Released May 6, 2021, after the close
10-Q filed May 7, 2021, 37 days after period end · 0001628280-21-009552
Q1 2021 · 10-Q
Revenue$32.79M$32.79M +18.7% vs Q1 2020−26.5% vs Q4 2020
Net Income-$18.82M-$18.82M N/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.25-$0.25 N/M vs Q1 2020N/M vs Q4 2020
Operating Income-$19,320,000N/M
Operating Cash Flow-$12,901,000N/M
Free Cash Flowderived-$19,824,000N/M
Margins · derived
Operating margin-58.9%−4.8 pt vs Q1 2020
Net margin-57.4%+0.5 pt vs Q1 2020
What the release said
The release
Same quarter
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Revenue | $32.79M | $27.62M | $30.11M | $25.25M |
| Net Income | -$18.82M | -$15.98M | -$25.47M | -$13.25M |
| EPS Diluted | -$0.25 | -$0.23 | -$0.44 | -$0.34 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR